Skip to main content
. Author manuscript; available in PMC: 2021 Sep 20.
Published in final edited form as: Immunohorizons. 2021 Jun 17;5(6):466–476. doi: 10.4049/immunohorizons.2100022

Figure 4. Antibodies against SARS-CoV-2 persist three months after COVID-19 symptom resolution.

Figure 4.

Sera from COVID-19 convalescent subjects collected 5 weeks (w) and 3 months (m) after symptom resolution were subjected to multiplex assay to detect IgG that binds to SARS-CoV-2 S, NTD, RBD and N antigens, to RBD-ACE2 binding inhibition assay, and to SARS-CoV-2 neutralization assay. Dots with lines connecting the two time points for individual subjects are shown for (A) all subjects (n=79), (B) hospitalized subjects (n=12), and (C) non-hospitalized subjects (n=67) with *p<0.05 and **p<0.01 by paired t test.